Drugs / Cybis™ 10:25
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04976738 | Sep 2021 → Jun 2022 | chronic pain syndrome | Cymra Life Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cybis 10:25 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04976738 ↗ |
| Known as | Cybis 10:25 THC:CBD oil | “Drug: Cybis™ 10:25 THC:CBD oil” NCT04976738 ↗ |
| Route | Other | “Cybis™ 10:25 will be administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily” NCT04976738 ↗ |